<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Virus Evol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Virus Evol</journal-id>
    <journal-id journal-id-type="publisher-id">vevolu</journal-id>
    <journal-title-group>
      <journal-title>Virus Evolution</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2057-1577</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6736041</article-id>
    <article-id pub-id-type="doi">10.1093/ve/vez002.009</article-id>
    <article-id pub-id-type="publisher-id">vez002.009</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Abstract Overview</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>A10 Presence and frequency of M184V mutation in the MOBIDIP trial</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Armero</surname>
          <given-names>A</given-names>
        </name>
        <xref ref-type="aff" rid="vez002.009-AFF1">1</xref>
        <xref ref-type="aff" rid="vez002.009-AFF2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chaix</surname>
          <given-names>M L</given-names>
        </name>
        <xref ref-type="aff" rid="vez002.009-AFF1">1</xref>
        <xref ref-type="aff" rid="vez002.009-AFF2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Nere</surname>
          <given-names>M L</given-names>
        </name>
        <xref ref-type="aff" rid="vez002.009-AFF1">1</xref>
        <xref ref-type="aff" rid="vez002.009-AFF2">2</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Delaporte</surname>
          <given-names>E</given-names>
        </name>
        <xref ref-type="aff" rid="vez002.009-AFF3">3</xref>
        <xref ref-type="aff" rid="vez002.009-AFF4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Peeters</surname>
          <given-names>M</given-names>
        </name>
        <xref ref-type="aff" rid="vez002.009-AFF3">3</xref>
        <xref ref-type="aff" rid="vez002.009-AFF4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Delaugerre</surname>
          <given-names>C</given-names>
        </name>
        <xref ref-type="aff" rid="vez002.009-AFF1">1</xref>
        <xref ref-type="aff" rid="vez002.009-AFF2">2</xref>
      </contrib>
    </contrib-group>
    <aff id="vez002.009-AFF1"><label>1</label>Virologie, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France</aff>
    <aff id="vez002.009-AFF2"><label>2</label>INSERM UMR 941, Université de Paris Diderot, Sorbonne Paris Cité, France</aff>
    <aff id="vez002.009-AFF3"><label>3</label>Institut de Recherche pour le Développement UMI 233, Montpellier, France</aff>
    <aff id="vez002.009-AFF4"><label>4</label>INSERM U1175, Université de Montpellier, Montpellier, France</aff>
    <pub-date pub-type="collection">
      <month>8</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2019-08-22">
      <day>22</day>
      <month>8</month>
      <year>2019</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>22</day>
      <month>8</month>
      <year>2019</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>5</volume>
    <issue>Suppl 1</issue>
    <issue-title>23rd International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology</issue-title>
    <elocation-id>vez002.009</elocation-id>
    <permissions>
      <copyright-statement>© Published by Oxford University Press.</copyright-statement>
      <copyright-year>2019</copyright-year>
      <license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>This is an Open Access publication distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
      </license>
    </permissions>
    <self-uri xlink:href="vez002.009.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>The MOBIDIP trial evaluated the simplification by protease (PI/r) monotherapy for HIV infection versus dual therapy and boosted protease inhibitor plus lamivudine (PI/r + 3TC) in controlled patients under second-line regimens. MOBIDIP was interrupted because of a significant number of patients with virological failure (VF) at week 48 (W48) in PI/r (33/133, ∼25%) versus in PI/r + 3TC (4/132, ∼3%). At the time of first-line VF, 96 per cent of patients harbored the M184V mutation. The presence of the M184V mutation was related to a protective effect against VF in the PI/r + 3TC arm. We developed a methodology that allows to determine the frequency of M184V/I mutations in the HIV reverse transcriptase (RT) gene in peripheral blood mononuclear cells (PBMC) obtained before MOBIDIP simplification. Paired-end sequences were obtained from 252 PBMC samples covering the first 855 bp of the RT gene (HXB2: 2485–3405) by MiSeq technology. These sequences were subjected to an in-house Bioinformatics pipeline. The results of our pipeline were compared to the output of PASeq (https://www.paseq.org), an open web-tool for the identification of drug resistance mutations. The M184V mutation was identified at a frequency greater than 1 per cent in 178 individuals (∼71%). The M184I mutation was observed in 34 patients (∼13%), always in the presence of stop codons, and is in agreement with expectations, as this mutation is a known APOBEC-targeted site. Sixty-seven patients (∼27%) had a frequency of the M184V mutation with values greater than 75 per cent. PASeq confirmed the presence of M184V mutation in 173 patients. The frequencies estimated by the PASeq tool and in-house pipeline were correlated up to 99.5 per cent. We found a significant loss of the M184V mutation archived in PBMC between the first-line regimen treatment failure and the beginning of the MOBIDIP trial. In patients under long-term antiretroviral therapy, as in our case, viral sub-populations could be lost, reducing the presence, and frequency of a mutation. In the next step, we will evaluate the association between the presence and frequency of M184V mutation and MOBIDIP results.</p>
    </abstract>
    <counts>
      <page-count count="2"/>
    </counts>
  </article-meta>
</front>
